[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kiniksa Pharmaceuticals International Plc (KNSA)

Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,193,545
  • Shares Outstanding, K 78,024
  • Annual Sales, $ 677,560 K
  • Annual Income, $ 59,010 K
  • EBIT $ 100 M
  • EBITDA $ 102 M
  • 60-Month Beta 0.05
  • Price/Sales 9.10
  • Price/Cash Flow 99.57
  • Price/Book 9.43

Options Overview Details

View History
  • Implied Volatility 47.16% (+3.71%)
  • Historical Volatility 71.23%
  • IV Percentile 15%
  • IV Rank 20.11%
  • IV High 93.62% on 09/25/25
  • IV Low 35.46% on 08/27/25
  • Expected Move (DTE 23) 7.06 (8.80%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 534
  • Volume Avg (30-Day) 736
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 3,816
  • Open Int (30-Day) 3,468
  • Expected Range 73.15 to 87.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.39
  • Number of Estimates 3
  • High Estimate $0.55
  • Low Estimate $0.31
  • Prior Year $0.23
  • Growth Rate Est. (year over year) +69.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.79 +27.73%
on 07/27/26
82.94 -3.30%
on 07/29/26
+17.36 (+27.63%)
since 07/24/26
3-Month
46.10 +73.97%
on 06/02/26
82.94 -3.30%
on 07/29/26
+26.96 (+50.64%)
since 05/22/26
52-Week
32.89 +143.84%
on 08/26/25
82.94 -3.30%
on 07/29/26
+47.16 (+142.74%)
since 08/25/25

Most Recent Stories

More News
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th...

KNSA : 80.20 (+1.03%)
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally

Kiniksa Pharmaceuticals is gaining momentum after strong ARCALYST sales growth, raised revenue guidance, and optimism surrounding its next-generation pipeline

KNSA : 80.20 (+1.03%)
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product...

KNSA : 80.20 (+1.03%)
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

LGND : 281.72 (+0.55%)
KNSA : 80.20 (+1.03%)
ASND : 252.99 (+0.41%)
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th...

KNSA : 80.20 (+1.03%)
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...

OTLK : 0.6400 (+5.09%)
KNSA : 80.20 (+1.03%)
CRMD : 8.56 (+3.38%)
PHAR : 11.77 (+2.71%)
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in...

KNSA : 80.20 (+1.03%)
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation.The...

KNSA : 80.20 (+1.03%)
CRMD : 8.56 (+3.38%)
CPRX : 31.49 (+0.03%)
PHAR : 11.77 (+2.71%)
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Shares of Precigen, Inc. PGEN have skyrocketed 144.4% in August so far, following the company's announcement of the FDA approval for Papzimeos (zopapogene imadenovec-drba) for the treatment of adults...

KNSA : 80.20 (+1.03%)
PGEN : 7.28 (+1.53%)
CRMD : 8.56 (+3.38%)
INO : 1.2900 (+3.20%)
Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas

For Immediate ReleaseChicago, IL – August 14, 2025 – Stocks in this week’s article are Modine Manufacturing Co. MOD, Tutor Perini Corp. TPC, Kiniksa Pharmaceuticals International plc KNSA, Life360...

KNSA : 80.20 (+1.03%)
MOD : 188.01 (-0.19%)
TPC : 87.33 (-1.12%)
LIF : 44.55 (+0.56%)
ESEA : 77.00 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa Pharmaceuticals International plc is based in LONDON.

See More

Key Turning Points

3rd Resistance Point 82.73
2nd Resistance Point 81.79
1st Resistance Point 81.00
Last Price 80.20
1st Support Level 79.27
2nd Support Level 78.33
3rd Support Level 77.54

See More

52-Week High 82.94
Last Price 80.20
Fibonacci 61.8% 63.82
Fibonacci 50% 57.92
Fibonacci 38.2% 52.01
52-Week Low 32.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.